Plain-English translation of NCT06057051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing the iStent Infinite, a tiny implant placed in the eye to help lower eye pressure in people with mild to moderate open-angle glaucoma. The implant works by creating a small pathway that allows fluid to drain more freely from inside the eye, which can reduce eye pressure. Researchers want to see whether this treatment works safely and effectively for patients like you.
Open-angle glaucoma damages vision by raising pressure inside the eye, and some patients don't get enough relief from eye drops alone or may need additional treatment options. This trial exists to gather real-world evidence about whether the implant can help patients manage their glaucoma better and preserve their vision.
You likely qualify if…
You likely don't qualify if…
If you join, you would undergo a surgical procedure to receive the tiny implant in your eye. You would then return for follow-up visits where doctors check your eye pressure, vision, and how well the implant is working. The trial involves multiple clinical sites, and your specific visit schedule will be explained by the research team at your location.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Sponsor
Glaukos Corporation
Enrollment target
~245 participants
Started
September 2023
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
35 Years and older
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dari Parizadeh
Glaukos Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.